There is strong evidence that deregulation of prolactin (PRL) signaling contributes to pathogenesis and chemoresistance of breast cancer. Therefore, understanding cross-talk between distinct signal transduction pathways triggered by activation of the prolactin receptor (PRL-R), is essential for elucidating the pathogenesis of metastatic breast cancer.
INTRODUCTION

Prolactin (PRL)
1 , a hormone secreted by the pituitary gland and to a lesser extent by other tissues, is involved in many diverse physiological processes, including reproduction and lactation, growth and development, metabolism, brain functioning, immunomodulation and osmoregulation [1] [2] . PRL acts as a growth, differentiating and survival factor in normal human mammary epithelial cells [3] . The levels of serum PRL and its receptor expression are increased in human breast cancer tissues [4] [5] [6] [7] [8] . PRL promotes neoplastic transformation by increasing cell proliferation in pre-invasive lesions, potentiates the transition to invasive carcinoma and is implicated in breast tumor resistance to chemotherapy [9] [10] .
PRL binding initiates conformational changes in the intracellular domains of dimerized class I cytokine family prolactin receptors (PRL-R) which leads to autophosphorylation and activation of their associated Janus family kinases (JAKs), followed by phosphorylation of PRL-R [11] [12] and stimulation of signal transducers and activators of transcription (STAT), phosphoinositide 3 (PI3)-kinase/Akt, Ras/mitogen activated protein kinase (MAPK) and other signaling pathways that control mitogenic, apoptotic, motogenic and cell differentiation responses [3, 13] . Aberrant activation of the three-tiered MAPK signaling cascade comprised of c-Raf, MEK1/2 (mitogen-activated protein kinase kinase 1/2) and ERK1/2 (extracellular signalregulated kinase 1/2) is common in many types of human cancers. Thus, the routes that positively regulate ERK1/2 activity toward its numerous cytosolic and nuclear effectors represent an attractive target for the development of anticancer drugs [14] .
Studying the regulatory connections in the PRL-R signaling network is essential for understanding the pathogenesis of metastatic breast cancer. Yet, the features of intra-and interpathway interactions (cross-talk) that lead to the emergent properties of the integrated cellular response are poorly understood. Therefore, with the goal of mapping the PRL-R signaling network architecture from receptor to ERK1/2, we examined the activation patterns of ERK1/2 in response to PRL and upon perturbations at different levels of network hierarchy in human breast cancer cell lines, derived from patients with invasive/infiltrative ductal carcinoma. Here, we unravel a pathway whereby the propagation of signals originating from PRL-R and leading to ERK1/2 activation via c-Raf, is largely controlled by a PI3-kinase-dependent, but Akt and STAT-independent, Rac/PAK (p21-activated kinase) route.
MATERIALS AND METHODS
Ligands, inhibitors, antibodies and chemicals
Prolactin was obtained from Peprotech Inc. (Rocky Hill, NJ). The stock solutions of inhibitors were prepared as recommended by the manufacturers. Lists of specific inhibitors and antibodies used in this study and their commercial sources are shown in Supplemental Table 1S and Table   2S , respectively. All other common chemicals, solvents and reagents were of highest grade available from various commercial sources. 
Cell stimulation, protein extraction and immunoprecipitation
Cells were plated in 60×15cm (for total cell lysates) or in 150×20 protein G Sepharose 4B bead slurry (Zymed Laboratories, Invitrogen), which was firstly preincubated with 5 µg of primary antibody against a specific protein for 2 hrs at RT. Alternatively, tyrosine-phosphorylated proteins were collected from supernatants with 50 µl of monoclonal anti-phosphotyrosine-agarose beads (pY-20) (Sigma-Aldrich) for 4 hrs at 4°C. Thereafter, the beads were washed twice in ice-cold immunoprecipitate washing buffer (150 mM NaCl, 20 mM HEPES (pH 7.4), 0.1% Triton-X100, 10% glycerol diluted in dH 2 O) and twice in ice-cold PBS.
The immunoprecipitated proteins were eluted in 1× NuPAGE LDS sample buffer (25% 4×
NuPAGE LDS sample buffer, 75% PBS) and heated for 5 min at 75°C.
Subcellular fractionation
Cells were grown in 100×20mm tissue culture dishes to confluence, starved overnight, stimulated as described above in the presence or absence of small molecule inhibitors, and incubated with 1.2 ml of ice-cold permeabilization buffer (150 mM NaCl, 2.5 mM EGTA, 50 mM HEPES, 10% glycerol, 150 µg/ml digitonin (Sigma-Aldrich) diluted in dH 2 O) for 10 min.
Afterwards, cells were gently collected into Eppendorf tubes and spun down for 2 min in an ultracentrifuge at max speed (10,000×g) at 4°C. Supernatant (cytosolic extract) was transferred into separate tube, and cell pellet, representing a crude membrane fraction, was resuspended in 150 µL of ice-cold lysis buffer. Extracts were centrifuged at 10,000×g for 10 min at 4°C to remove debris and the supernatants were resuspended in Laemmli buffer as indicated above.
Cytosolic and particulate fractions were then assayed for protein translocation and activation.
Ras and Rac1 activation assays
Active (GTP-bound) Ras and Rac1 from 500 µg total cell lysates were captured with 30 µl of Ras-GTP or Rac1-GTP proteins were released from agarose beads with NuPAGE LDS sample buffer and heated for 5 min at 75°C.
Transient cell transfection with siRNA
Half an hour or less before transfection MCF-7 cells were trypsinized and resuspended in antibiotic-free complete media. 1. Table 3S . Cell suspensions containing siRNA were electroporated using the P-020 program on Amaxa's Nucleofector II device (Lonza Cologne AZ, Basel, Switzerland). Immediately after electroporation, 0.5 ml of the pre-equilibrated antibiotic-free complete media was added to the cuvette and the cell suspension was gently transferred into 6-well plates (final volume 2.0 ml media per well). Cells were allowed to attach for 6 hours before the addition of penicillin-streptomycin solution. Total proteins were isolated from cells harvested 72 hours post-transfection.
Real-time qPCR
To estimate the level of suppression of target mRNAs in response to siRNA transfection, total RNA was isolated using RNeasy Plus kit (Qiagen) according to the manufacturer's protocol from total cell lysates prepared 72 hours post-transfection. RNA (0.5-2 µg) was reverse-transcribed with SuperScript III First-strand reverse transcriptase system using oligo-dT primers (Invitrogen) Relative mRNA abundance was normalized to the internal standard GAPDH by the ∆∆CT method, as described by the manufacturer (Invitrogen).
Gel electrophoresis, immunoblotting and data evaluation
Protein separation by gel electrophoresis and Multistrip Western blotting procedures were performed as described previously [15] . Briefly, samples were subjected to LDS-PAGE under reducing conditions. Resolved proteins were transferred onto nitrocellulose membranes, which were afterwards blocked in 3% bovine serum albumin (BSA) solution for 1 h at RT, kept with indicated primary antibodies overnight at RT, extensively washed with TBS-T washing buffer 
Wound healing assay
Cells grown to confluence in 6-well plates were scratched using a pipette tip to create a wound, washed with serum-free medium to remove loosened cells, and then cultured in serum-free medium that contained PRL with or without small molecule inhibitors, with medium being replaced every 24 hours. Cells were photographed at 0 and 72 hours after wounding with an inverted light microscope at 4× magnification. Experiments were performed in triplicate. Area of each wound surface was quantitated using Adobe Photoshop software (Mountain View, CA).
The mean percentage wound closure was calculated using the equation (S2-S1)/S2*100, where S2 is cell-free scratch area at 0 h after wounding, S1 -cell-free scratch area at 72 hours after wounding.
Cell growth/viability assay
Cells were plated in quadruplicates into 24-well plates at a density of 20,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low serum-containing medium (1% FBS) supplemented with 10 nM PRL with or without inhibitors. To evaluate cell growth and viability 72 hours after inhibitor treatment, the AlamarBlue assay (Invitrogen, Carlsbad, CA) was performed as described previously [16] . Results are expressed as percentage of control and presented as the mean ± SD obtained from three independent experiments.
RESULTS
Prolactin concomitantly activates c-Src, JAK/STAT, PI3K/Akt and MAPK signaling cascades
The ability of recombinant human PRL to stimulate its cognate receptor and activate Janus family kinases (JAKs) was examined by probing the immunoprecipitates of tyrosinephosphorylated proteins from lysates of non-stimulated and PRL-treated T47D cells with specific anti-PRL-R, anti-JAK2 or anti-JAK1 antibodies. The results show that PRL induced a strong tyrosine phosphorylation of PRL-R and JAK2, but not JAK1, compared to non-stimulated cells (Fig. 1A) .
Because PRL-R and JAK2 colocalize with cytosolic src avian sarcoma viral oncogen homolog (c-Src) in lipid-rich fractions of the plasma membrane [17] , we assessed whether c-Src was activated in response to PRL in breast cancer cells by measuring the phosphorylation state of c-Src at Tyr416, located in the activation loop of the kinase domain, which is required for maximum c-Src enzyme activity [18] . Western blotting analysis using the phosphospecific Src
Tyr416 antibody showed that c-Src phosphorylation increased nearly 2-fold above basal level after 2 min PRL treatment, reached a peak at 5 min (2.5-fold) and returned to the basal level by 60 min (Fig. 1B) . As further evidence for increased c-Src activity, we also followed the phosphorylation kinetics of its effector focal adhesion kinase (FAK) on Tyr925 (Fig. 1C) , a major target site for c-Src [19] .
The potency of PRL to transduce the signals through its receptor to multiple branches of intracellular signaling pathways was then verified by monitoring the activation patterns of the STATs, PI3-kinase/Akt and MAPK signaling cascades (Fig. 2 ). Our results demonstrate that stimulation of T47D cells with PRL promoted an increase in the phosphorylation of STAT5 at Tyr694 ( Fig. 2A , left panel), STAT3 at Tyr705 ( Fig. 2A , middle panel) and STAT1 at Tyr701, as revealed by site-specific antibodies that recognized the phosphorylated state of respective residues. Phosphorylation of these sites on STATs is obligatory for their homo-and heterodimerization, nuclear translocation and binding to specific DNA elements in the promoters of signal-responsive genes [20] . Consistent with other observations [21] , no detectable levels of phospho-STAT3 were detected in MCF-7 cells, which also had less pronounced phosphorylation of STAT5 and STAT1 proteins compared to T47D cells ( Fig. 2A) . Phosphorylation levels of the serine/threonine kinase Akt on Ser473 were assessed as readout of PI3-kinase activity in response to PRL ( 
2S. Although inhibition of SFKs did not change the autophosphorylation status of JAK2 on
Tyr1007/Tyr1008 residues (Fig. 3A, blot 1) , which lie within the kinase domain and regulate kinase activity [28] , the phosphorylation of STAT5 on Tyr694 (Fig. 3A, blot 2 ) and focal adhesion kinase (FAK) on Tyr925 (Fig. 3A, blot 4) were significantly attenuated. This observation suggests that SFKs lie upstream of these proteins, but may be downstream of JAK2.
Once phosphorylated on Tyr925, FAK is predicted to recruit growth factor receptor-bound protein 2 (Grb2), an adaptor protein known to be involved in Ras/MAPK signaling [29] . In the canonical Ras/MAPK signaling pathway, Grb2 binds phosphotyrosine motifs via the Src homology 2 (SH2) domain, while two flanking Src homology 3 (SH3) domains bind Son of Sevenless (SOS), the guanine nucleotide exchange factor (GEF) for small GTPase Ras which acts upstream of the Raf/MEK/ERK cascade [30] .
Su6656 treatment abrogated the phosphorylation of Grb2-associated binder 1 (Gab1) on Tyr627 residue (Fig. 3A, blot 5) , which is required for binding of the protein tyrosine phosphatase SHP2, with its subsequent phosphorylation on Grb2-binding sites (Tyr542 and Tyr580) by upstream kinases and an increase in phosphatase activity [31] [32] [33] . SHP2 can positively regulate STAT5 signaling [34] [35] and activate Ras through multiple mechanisms [31] .
Our data show that SFKs are responsible for SHP2 phosphorylation in PRL signaling (Fig. 3A, blot 6). At the same time Su6656 treatment dramatically suppressed the PRL-induced activation of Akt (Fig. 3A, blot 7) , MEK (Fig. 3A, blot 8 ) and ERK1/2 ( Fig. 3A, blot 9 ). Glyceraldehyde-3-Phosphate Dehyrogenase (GAPDH) protein levels were used as a control for equal protein loading (Fig. 3A, blot 10 ). Similar inhibitory effects of Su6656 treatment on PRL-induced phosphorylation of STAT5 (Fig. 3B , white bars), Akt ( Based on these results, indicating that SFKs are required for PRL-mediated ERK1/2 activation in breast cancer cells, we further determined the quantitative contribution of immediate SFK substrate FAK to major signaling pathways by using the specific FAK inhibitor PF573228 [36] .
Growth factors facilitate autophosphorylation of FAK at Tyr397, which is a critical residue for the activation and function of FAK, and serves as a docking site for SFKs and p85 regulatory subunit of PI3-kinase [37] [38] . Recruitment of SFKs results in the phosphorylation of Tyr407, Tyr576 and Tyr577 in the catalytic domain, and Tyr871 and Tyr925 in the carboxyterminal region of FAK [39] [40] . PRL-induced phosphorylation of FAK at Tyr397, Tyr576, Tyr577 and Tyr925 residues was suppressed by treating T47D cells with PF573228 (Fig. 3C , blots 1-3) without affecting total levels of FAK (Fig. 3C, blot 4) and GAPDH (Fig. 3C, blot   10 ). PF573228 treatment did not interfere with the activation of SFKs (Fig. 3C, blot 5 ), but slightly reduced tyrosine phosphorylation of STAT5 (Fig. 3C, blot 6 ) as well as attenuated Akt (Fig. 3C, blot 7) and MEK/ERK responses ( another member of the JAK family, but not those of JAK1 and c-Src [42] . As expected, NIF treatment decreased JAK2 and STAT5 tyrosine phosphorylation and greatly reduced ERK1/2 activation (>90%) in PRL-stimulated MCF-7 cells, whereas total ERK1/2 protein levels remained unaffected (Fig. 4C) . Of note, T47D appeared to be much more resistant to NIF treatment. These data indicate that JAK2-dependent activation of proteins other than STATs mediate the PRL-induced activation of ERK1/2 in breast cancer cells.
PI3-kinase-mediated ERK activation via c-Raf occurs regardless of downstream Akt signaling
We next explored the possibility that SFK/FAK-dependent ERK1/2 responses could be modulated by the PI3-kinase/Akt signaling pathway, which, as shown above, is strongly suppressed by SFKs inhibition (Fig. 3A, blot 7) and partially depends on FAK activity (Fig. 3C,   blot 7) . For this purpose, T47D cells were pretreated with wortmannin (WT), a specific covalent inhibitor of class I, II and III PI3-kinases, and stimulated with PRL for different time intervals. The complete inhibition of inducible Akt phosphorylation at Ser473 (Fig. 5A, blot 1) in the presence of WT upon PRL stimulation confirmed that the 200 nM WT dose effectively inhibited the production of phosphoinositol-triphosphate PI(3,4,5)P 3 by PI3-kinase and activation of the PI3-kinase/Akt pathway. PI3-kinase inhibition nearly completely prevented early and late signal propagation throughout the whole MAPK cascade, starting with c-Raf on its activating Ser338 residue (Fig. 5A, blot 6) to MEK (Fig. 5A, blot 7) and to ERK1/2 (Fig. 5A, blot 8 ). This effect was not due to inhibitor-induced changes in the expression levels of Akt (Fig. 5A, blot 2) or ERK1/2 (Fig. 5A, blot 9 ). PI3-kinase inhibition did not reduce the phosphorylation of SFKs at Tyr416 (Fig. 5A, blot 3) , indicating that SFKs act upstream of PI3-kinase and are not responsible for WT-induced changes in ERK1/2 activation. Of note, the PRL-induced increases in STAT5 and STAT3 tyrosine phosphorylation levels were not inhibited by WT (Fig. 5A, blots 4-5), in agreement with the observation from the inhibition studies shown in Fig. 4 that STATs do not participate in MAPK activation.
In order to obtain further evidence for the involvement of class I PI3-kinase in ERK1/2 activation in PRL signaling, we used a selective inhibitor for the α-isoform of PI3-kinase, PI3K-α inhibitor 2. As a result of this treatment, peak ERK1/2 phosphorylation was decreased by 60% in T47D cells and by 80% in MCF-7 cells. This level of inhibition was similar to that obtained upon treatment with WT (70% and 83%) or LY294002 (63% and 72%) in T47D cells (Fig. 5B, upper panel) and MCF-7 (Fig. 5B, lower panel) cells, respectively.
Importantly, cell treatment with WT did not change overall tyrosine phosphorylation levels of PRL-R, JAK2 and p52/p46 Shc adaptor proteins, which are presumed to bind the Grb2-SOS complex, which couples Shc to the Ras activated MAPK pathway (Fig. 5C) . Consistently, PI3-kinase inhibition failed to reduce the amounts of Grb2 that inducibly associated with Shc upon PRL stimulation, as shown by immunoblotting of Shc precipitates with anti-Grb2 antibodies (Fig. 5D) , indicating that suppression of Shc-Grb2 complex formation was not responsible for the inhibition of ERK1/2 activation. By contrast, suppressing PI(3,4,5)P 3
formation by PI3-kinase inhibition significantly reduced the membrane recruitment (Supplemental Fig. 3S ) and tyrosine phosphorylation of pleckstrin homology (PH) domaincontaining Gab proteins (Fig. 5C) , which could potentially affect SHP2 activation. However, neither tyrosine phosphorylation of SHP2 nor its recruitment to the plasma membrane were significantly altered by WT (Supplemental Fig. 3S) , implying that the functioning of SHP2 may depend on proteins that lack PH-domain(s) and therefore are independent of PI3-kinase. Thus, neither of these well-established mechanisms of activation of the MAPK cascade could account for the sensitivity of PRL-induced ERK activation to PI3-kinase inhibitors.
Next, in order to evaluate the contribution of Akt, an immediate effector of PI3-kinase, and its downstream targets to ERK1/2 activation, the cells were pretreated with an isozymeselective Akt1/2/3 inhibitor (Akt-VIII), which does not interfere with the PI3-kinase activity per se. As shown in Fig. 5E , Akt inhibition had no significant effect on ERK1/2 phosphorylation in T47D and MCF-7 cells upon PRL-treatment. This observation demonstrates that the proteins that are critical for ERK1/2 activation either operate downstream of PI3-kinase, but upstream of Akt (e.g. PDK1), or belong to a distinct PI3-kinase-dependent signaling branch such as Rac/Cdc42/PAK. Therefore, next we examined the contribution of group I PAK kinases (PAK1/2/3) and their upstream effectors to ERK1/2 activation.
Prevalence of Rac/PAK pathway in prolactin-induced ERK activation
Although inhibition of PI3-kinase did not prevent c-Raf recruitment to the plasma membrane ( Fig. 6A) , it considerably reduced PRL-induced c-Raf phosphorylation at Ser338
( Fig. 6B and Fig. 5A, blot 6 ), which correlated with a decreased phosphorylation of serine/threonine kinases PAK1/2 on activating Thr423/Thr402 residues (Fig. 6B) , supporting the notion that Ser338 is a target site for PAK1 [43] .
The multi-step activation of PAK involves its interaction with PAK-interacting exchange factor (PIX), which recruits PAK to the small GTPases Rac and Cdc42, resulting in relief from autoinhibition, autophosphorylation and/or phosphorylation by exogenous kinases. In addition, a GTPase-independent PAK activation mechanisms also exist [44] [45] .
Pull-down experiments using the p21-binding domain (PBD) of PAK to selectively isolate the GTP-bound form of Rac1 showed that PRL was able to induce activation of Rac1 in breast cancer cells (Fig. 6C) . Next, T47D and MCF-7 cells were stimulated with PRL for various periods of time in the presence or absence of PAK18, which is composed of the cell permeant TAT peptide sequence and an 18-mer proline-rich PIX-interacting motif of PAK that disrupts PIX-PAK interaction and thereby reduces PAK activation by Rac1 and Cdc42 [43] .
Alternatively, cells were pretreated with the allosteric PAK inhibitor IPA-3, which promotes an inactive conformation of PAK1, but does not inhibit the enzymatic activity of preactivated PAKs [46] [47] .
Along with its well-known downstream target p38 MAPK [48] , PAK inhibition significantly reduced the activation of c-Raf, MEK and ERK1/2 following 15 min of PRL stimulation in T47D cells (Fig. 6D) . More detailed measurements of the temporal phosphorylation response of ERK1/2 revealed that treatment with PAK18 and IPA-3 decreased peak ERK1/2 activation by 66% and 65% in T47D cells (Fig. 6E, left panel) and by 60% and 54% in MCF-7 cells (Fig. 6E, right panel) , respectively. Next, we used EHT 1864, a small molecule inhibitor of Rac family small GTPases (Rac1, Rac1b, Rac2 and Rac3), which prevents Rac interaction with all effectors, including PAKs [49] . In comparison with untreated cells, EHT 1864 treatment reduced maximal ERK1/2 activation by 74% in T47D (Fig. 6E, left panel) and by 88% in MCF-7 (Fig. 6E, right panel) cells.
PRL enhances the motility of T47D, MCF-7, and MDA-231 breast cancer cell lines and potentiates EGF-induced migration [50] . In our study, the inhibitory effect of EHT 1864 on cell migration was examined using a wound-healing assay. Rac inhibition significantly reduced PRLinduced motility of MCF-7 cells (Supplemental Fig. 4S ). In addition, Rac/PAK inhibition by IPA-3 and EHT 1864 significantly reduced PRL-mediated T47D breast cancer cell growth in vitro (Supplemental Fig. 5S ).
Apart from its activation by small GTPases Rac and Cdc42, PAKs can also bind to Grb2
[51] and be recruited to activated receptors on the plasma membrane, where PDK1 can phosphorylate PAK1 at Thr423, a residue that is critical for PAK1 activation, by disrupting the folded autoinhibitory conformation [52] [53] [54] . Therefore, to ensure a complete suppression of PAK1 activation, we used OSU-03012, a novel Celecoxib derivative, which simultaneously inhibits PDK1 activity, thus blocking the PDK1-mediated PAK1 activation route, as well as inhibiting PAK activity via competitive inhibition of ATP binding [55] . OSU-03012 treatment nearly abolished PRL-induced Akt and ERK1/2 responses in MCF-7 cells (Fig. 6F ) and T47D cells (Fig. 6G) (Fig. 7) . Inability to block ERK1/2 activation by 100% by Rac1 siRNA may indicate that ERK1/2 can be also activated by the other isoforms and members of the Rac family, such as Rac1b, Rac2, Rac3 and/or Cdc42.
Ras plays a minor role in prolactin-induced ERK activation
Our data show that PRL-stimulated T47D and MCF-7 cells display very low activation of the small GTPase Ras over a basal level compared to the potent Ras-inducer heregulin-β (HRG-β) (Fig. 8A) . Moreover, PRL-activated Ras corresponds to only a small fraction of the total pool of Ras-GTP (Fig. 8A) . and simultaneously increased Ras protein levels in cytosol (Fig. 8B) . However, manumycin A treatment had no effect on the initial rate of increase in ERK1/2 phosphorylation and only a moderately suppressed it at time points of 30 minutes or longer in either T47D (Fig. 8C) or MCF-7 (Fig. 8D) cells. Similar effects were obtained with another farnesyltransferase inhibitor Ras FTase III (Fig. 8C-D) and siRNA against K-RAS, which downregulated the K-Ras protein levels by 70%, but failed to block the phosphorylation of ERK1/2 and Akt (Supplemental Moreover, simultaneous inhibition of PDK1 and PAKs abrogated the ERK1/2 responses to PRL in T47D, MCF-7 and SK-BR-3 breast cancer cell lines, thereby generalizing our observations that activated PRL-R largely utilizes the PI3-kinase-dependent Rac/PAK pathway rather than the canonical Shc/Grb2/SOS/Ras route to initiate, augment and sustain ERK1/2 signaling.
This conclusion is further supported by the minimal effect of Ras inactivation by the use of farnesyl transferase inhibitors or K-RAS siRNA. However, we cannot exclude that Ras inhibition was incomplete or that the contribution of K-RAS to ERK and Akt activation may be readily compensated by other Ras isoforms (e.g. H-Ras, N-Ras). Moreover, using higher concentrations of the farnesyl transferase inhibitors to eliminate all functional Ras from the plasma membrane caused significant Akt dephosphorylation, followed by ERK1/2 deactivation (Supplemental Fig. 10S ) and cell detachment and death, possibly due to deregulation of antiapoptotic pathways as a consequence of Ras inhibition or other effects of defarnesylation [64] .
Therefore, these approaches could not be used to quantify more accurately the contributions of Ras-dependent and Ras-independent inputs into ERK1/2.
A general picture emerges from our results, in conjunction with prior studies, in which the signaling from PRL-R/JAKs/SFKs diverges into four major pathways: STATs, PI3-kinase/Akt, Rac/PAK and Shc/Grb2-SOS/Ras (Fig. 9) . The signal to ERK1/2 is predominantly routed through the PI3-kinase/PDK1-dependent Rac/PAK/c-Raf/MEK route. In parallel, the Rac/PAK pathway also feeds into the stress response MAPK cascades, such as p38MAPK. By activating these pathways, PLR can perform important functions in controlling cell cycle entry, apoptosis, cell shape, polarity, adhesion as well as migration. Given that more than 50% of human breast cancers display overexpression and hyperactivation of PAK1/2 and/or PI3-kinase, which correlate with increased invasiveness and survival of breast cancer cells [65] [66] [67] , our findings provide a more detailed roadmap by which these pathways are integrated, which is likely to be relevant for therapeutic interventions that target these pathways and therefore may have clinical significance.
Clearly, further studies are required to accurately quantify the contributions of these different signaling routes leading to ERK1/2 activation and related downstream cascades in tumor and non-malignant cells and to assess their impact on physiological outcomes related to tumorigenesis and metastatic potential. Such studies will form the basis for a more complete computational analysis of the integrated PRL-R signaling network in which the roles of protein phosphatases and multiple feedback loops can be quantified.
CONCLUSION
In conclusion, our systems-level analysis of PRL signaling network demonstrates the interplay between the PI3-kinase and MAPK signaling cascade, which, to the best of our knowledge, has never been studied in the context of PRL signaling. Our data reveal that the signal from the activated PRL receptor to ERK1/2 predominantly uses the PI3-kinase-dependent
Rac/PAK/c-Raf/MEK pathway rather than the canonical Shc/Grb2/SOS/Ras route. In turn, the PI3-kinase-dependent ERK1/2 activation is controlled by JAK2, Src family kinases and FAK, whereas STATs, Akt and PKC do not regulate PRL-induced ERK1/2 responses. At the same time, Rac/PAK inhibiton or silencing by siRNA significantly suppresses PRL-mediated breast cancer cell growth and motility. Thus our study highlights the rationale for targeting Rac/PAK signaling pathway alone or in combination with PI3-kinase and/or Src-directed therapies in breast cancer.
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